Trolamine salicylate

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Trolamine salicylate
Accession Number
DB11079
Type
Small Molecule
Groups
Approved
Description

Trolamine salicylate is an organic compound which is the salt formed between triethanolamine and salicylic acid. The triethanolamine neutralizes the acidity of the salicylic acid. It is a topical analgesic used for temporary relief of minor pain associated with arthritis, simple backache, muscle strains, sprains, and bruises. Unlike other topical analgesics, trolamine salicylate has no distinguishable odor.

Structure
Thumb
Synonyms
Not Available
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Actiflex Pain Relief RubCream10 %TopicalPendopharm Division Of De Pharmascience Inc2003-01-202011-09-30Canada
Alcis Daily Relief Pain ReliefCream10 g/100mLTopicalAlcis Topical, Inc.2009-03-09Not applicableUs
Alcis Topical Pain Relief CreamCream10 %TopicalAlcis Health Inc.Not applicableNot applicableCanada
AnalgesicCream10 g/100gTopicalMeijer Distribution1990-04-152017-11-22Us
Analgesic CreamCream15 %TopicalPharmascience Inc2013-10-08Not applicableCanada
Analgesic Cream Extra Strength OdorlessCream15 %TopicalPharmascience Inc1999-10-09Not applicableCanada
Analgesic Creme RubCream100 mg/gTopicalMajor2014-05-10Not applicableUs
Antiphlogistine Rub A-535 No Odour Fmla OntOintment13.3 %TopicalCarter Products, Division Of Carter Wallace Ns Inc.1993-12-311997-08-14Canada
ArthricreamCream10 g/100gTopicalWalmart Stores2009-04-25Not applicableUs
ArthricreamCream10 g/100gTopicalKroger1992-02-04Not applicableUs
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Pain Relief CreamCream100 mg/gTopicalAllure Labs, Inc.2017-11-27Not applicableUs
Up and Up Odor-free Pain Relieving CreamCream8.5 g/85gTopicalTarget Corporation.2017-11-29Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Arthritis Extra Strength Roll-ON LotionTrolamine salicylate (10 %) + Capsaicin (0.035 %) + Menthol (1.25 %)LotionTopicalChurch & Dwight Company, Inc.2008-09-15Not applicableCanada
Arthur Itis CreamTrolamine salicylate (10 %) + Capsaicin (0.025 %)CreamTopicalNabtech Pharma Inc.1997-09-262005-09-20Canada
Ease Pain Away Analgesic LotionTrolamine salicylate (10 %) + Menthol (1.25 %)LotionTopicalRmc Group Inc.1994-12-311999-11-23Canada
ELF Flawless Finish Foundation SPF 15 Oil FreeTrolamine salicylate (2 g/100g) + Titanium dioxide (5.5 g/100g)CreamTopicalJ. A. Cosmetics U.S. INC2011-10-03Not applicableUs
Myoflex Extra Strength IceTrolamine salicylate (15 %) + Menthol (3 %)GelTopicalBayer Inc Consumer Care2003-10-302007-08-02Canada
Myoflex Ice Cold Plus - GelTrolamine salicylate (15 %) + Menthol (3 %)GelTopicalBayer Inc Consumer Care1996-09-101997-08-01Canada
Myoflex Ice Cold Plus - GelTrolamine salicylate (15 %) + Menthol (3 %)GelTopicalSterling Winthrop Inc.1994-12-311996-09-10Canada
Myoflex Ice Plus - CrmTrolamine salicylate (15 %) + Menthol (3 %)CreamTopicalBayer Inc Consumer Care1994-12-302004-06-28Canada
Permavan External PatchTrolamine salicylate (10 g/100g) + Dextromethorphan hydrobromide (4 g/100g) + Lidocaine (4 g/100g)PatchTopicalHome Aide Diganostics, Inc.2015-03-09Not applicableUs
Categories
UNII
H8O4040BHD
CAS number
2174-16-5
Weight
Average: 287.312
Monoisotopic: 287.1368874
Chemical Formula
C13H21NO6
InChI Key
UEVAMYPIMMOEFW-UHFFFAOYSA-N
InChI
InChI=1S/C7H6O3.C6H15NO3/c8-6-4-2-1-3-5(6)7(9)10;8-4-1-7(2-5-9)3-6-10/h1-4,8H,(H,9,10);8-10H,1-6H2
IUPAC Name
2-[bis(2-hydroxyethyl)amino]ethan-1-ol; 2-hydroxybenzoic acid
SMILES
OCCN(CCO)CCO.OC(=O)C1=CC=CC=C1O

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with 5-androstenedione.Experimental, Illicit
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Trolamine salicylate.Approved
AcenocoumarolTrolamine salicylate may increase the anticoagulant activities of Acenocoumarol.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Acetazolamide.Approved, Vet Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Trolamine salicylate.Approved, Vet Approved
AlclometasoneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Aldosterone.Experimental, Investigational
AloxiprinThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Aloxiprin.Experimental
AlprostadilThe risk or severity of adverse effects can be increased when Alprostadil is combined with Trolamine salicylate.Approved, Investigational
AlteplaseThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Alteplase.Approved
AmcinonideThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Amcinonide.Approved
Aminosalicylic AcidAminosalicylic Acid may increase the anticoagulant activities of Trolamine salicylate.Approved
Ammonium chlorideThe serum concentration of Trolamine salicylate can be increased when it is combined with Ammonium chloride.Approved, Vet Approved
AnagrelideThe risk or severity of adverse effects can be increased when Anagrelide is combined with Trolamine salicylate.Approved
AncrodTrolamine salicylate may increase the anticoagulant activities of Ancrod.Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Trolamine salicylate.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with anecortave acetate.Investigational
AnistreplaseThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Anistreplase.Approved
Antithrombin III humanTrolamine salicylate may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanTrolamine salicylate may increase the anticoagulant activities of Apixaban.Approved
ArdeparinTrolamine salicylate may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanThe risk or severity of adverse effects can be increased when Argatroban is combined with Trolamine salicylate.Approved, Investigational
AstaxanthinThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Astaxanthin.Investigational
AtamestaneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Atamestane.Investigational
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Trolamine salicylate.Approved
BalsalazideBalsalazide may increase the anticoagulant activities of Trolamine salicylate.Approved, Investigational
BatroxobinThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Batroxobin.Experimental
BecaplerminTrolamine salicylate may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Beclomethasone dipropionate.Approved, Investigational
BemiparinThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Bemiparin.Approved, Investigational
BenazeprilTrolamine salicylate may decrease the antihypertensive activities of Benazepril.Approved, Investigational
BeraprostThe risk or severity of adverse effects can be increased when Beraprost is combined with Trolamine salicylate.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Betamethasone.Approved, Vet Approved
BivalirudinTrolamine salicylate may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BrinaseThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Brinase.Experimental
BrinzolamideThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Brinzolamide.Approved
BudesonideThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Budesonide.Approved
BuflomedilThe risk or severity of adverse effects can be increased when Buflomedil is combined with Trolamine salicylate.Experimental
BumetanideTrolamine salicylate may decrease the diuretic activities of Bumetanide.Approved
ButylphthalideThe risk or severity of adverse effects can be increased when Butylphthalide is combined with Trolamine salicylate.Investigational
CandoxatrilTrolamine salicylate may decrease the antihypertensive activities of Candoxatril.Experimental
CangrelorThe risk or severity of adverse effects can be increased when Cangrelor is combined with Trolamine salicylate.Approved
CaplacizumabThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Caplacizumab.Investigational
CaptoprilTrolamine salicylate may decrease the antihypertensive activities of Captopril.Approved
Carbaspirin calciumCarbaspirin calcium may increase the anticoagulant activities of Trolamine salicylate.Experimental, Investigational
CertoparinTrolamine salicylate may increase the anticoagulant activities of Certoparin.Approved, Investigational
CiclesonideThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Ciclesonide.Approved, Investigational
CilazaprilTrolamine salicylate may decrease the antihypertensive activities of Cilazapril.Approved
CilostazolThe risk or severity of adverse effects can be increased when Cilostazol is combined with Trolamine salicylate.Approved
Citric AcidTrolamine salicylate may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Clocortolone.Approved
ClopidogrelThe risk or severity of adverse effects can be increased when Clopidogrel is combined with Trolamine salicylate.Approved
CloricromenThe risk or severity of adverse effects can be increased when Cloricromen is combined with Trolamine salicylate.Experimental
ClorindioneTrolamine salicylate may increase the anticoagulant activities of Clorindione.Experimental
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Cortisone acetate.Approved
Dabigatran etexilateTrolamine salicylate may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinTrolamine salicylate may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidTrolamine salicylate may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanTrolamine salicylate may increase the anticoagulant activities of Darexaban.Investigational
DefibrotideThe risk or severity of adverse effects can be increased when Defibrotide is combined with Trolamine salicylate.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Deflazacort.Approved, Investigational
DelaprilTrolamine salicylate may decrease the antihypertensive activities of Delapril.Experimental
DersalazineDersalazine may increase the anticoagulant activities of Trolamine salicylate.Investigational
DesirudinTrolamine salicylate may increase the anticoagulant activities of Desirudin.Approved
DesmoteplaseThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Desmoteplase.Investigational
DesonideThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Dexketoprofen.Approved, Investigational
DextranTrolamine salicylate may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Trolamine salicylate may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Trolamine salicylate may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Trolamine salicylate may increase the anticoagulant activities of Dextran 75.Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Diclofenamide.Approved
DicoumarolTrolamine salicylate may increase the anticoagulant activities of Dicoumarol.Approved
DiflorasoneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Diflorasone.Approved
DiflunisalDiflunisal may increase the anticoagulant activities of Trolamine salicylate.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Difluprednate.Approved
DiltiazemDiltiazem may increase the anticoagulant activities of Trolamine salicylate.Approved
DiphenadioneTrolamine salicylate may increase the anticoagulant activities of Diphenadione.Experimental
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Trolamine salicylate.Approved
DitazoleThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Ditazole.Approved, Withdrawn
DorzolamideThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Dorzolamide.Approved
Drotrecogin alfaThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Drotrecogin alfa.Approved, Investigational, Withdrawn
Edetic AcidTrolamine salicylate may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanTrolamine salicylate may increase the anticoagulant activities of Edoxaban.Approved
EnalaprilTrolamine salicylate may decrease the antihypertensive activities of Enalapril.Approved, Vet Approved
EnalaprilatTrolamine salicylate may decrease the antihypertensive activities of Enalaprilat.Approved
EnoxaparinTrolamine salicylate may increase the anticoagulant activities of Enoxaparin.Approved
EpinastineThe risk or severity of adverse effects can be increased when Epinastine is combined with Trolamine salicylate.Approved, Investigational
EplivanserinThe risk or severity of adverse effects can be increased when Eplivanserin is combined with Trolamine salicylate.Investigational
eplivanserineThe risk or severity of adverse effects can be increased when eplivanserine is combined with Trolamine salicylate.Investigational
EpoprostenolThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Trolamine salicylate.Approved
EptifibatideThe risk or severity of adverse effects can be increased when Eptifibatide is combined with Trolamine salicylate.Approved, Investigational
EquileninThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Equilin.Approved
EstroneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Estrone sulfate.Approved
Etacrynic acidTrolamine salicylate may decrease the diuretic activities of Etacrynic acid.Approved
EthoxzolamideThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Ethoxzolamide.Withdrawn
Ethyl biscoumacetateTrolamine salicylate may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Ferulic acidTrolamine salicylate may increase the anticoagulant activities of Ferulic acid.Experimental
FibrinolysinThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Fibrinolysin.Investigational
FluasteroneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Fludrocortisone.Approved
FluindioneTrolamine salicylate may increase the anticoagulant activities of Fluindione.Investigational
FlumethasoneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Flunisolide.Approved, Investigational
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Fluorometholone.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Fluprednisolone.Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Flurandrenolide.Approved
Fluticasone furoateThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Fluticasone propionate.Approved
FondaparinuxTrolamine salicylate may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumTrolamine salicylate may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
FormestaneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilTrolamine salicylate may decrease the antihypertensive activities of Fosinopril.Approved
FurosemideTrolamine salicylate may decrease the diuretic activities of Furosemide.Approved, Vet Approved
GabexateTrolamine salicylate may increase the anticoagulant activities of Gabexate.Investigational
Ginkgo bilobaGinkgo biloba may increase the anticoagulant activities of Trolamine salicylate.Approved, Investigational, Nutraceutical
GuacetisalGuacetisal may increase the anticoagulant activities of Trolamine salicylate.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Halcinonide.Approved, Investigational, Withdrawn
HE3286The risk or severity of adverse effects can be increased when Trolamine salicylate is combined with HE3286.Investigational
Hemoglobin crosfumarilHemoglobin crosfumaril may increase the anticoagulant activities of Trolamine salicylate.Experimental
HeparinTrolamine salicylate may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Higenamine.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Trolamine salicylate.Approved, Investigational
HydrocortisoneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Hydrocortisone.Approved, Vet Approved
HydroxytyrosolThe risk or severity of adverse effects can be increased when Hydroxytyrosol is combined with Trolamine salicylate.Investigational
IbudilastThe risk or severity of adverse effects can be increased when Ibudilast is combined with Trolamine salicylate.Approved, Investigational
Icosapent ethylThe risk or severity of adverse effects can be increased when Icosapent ethyl is combined with Trolamine salicylate.Approved, Nutraceutical
IdraparinuxTrolamine salicylate may increase the anticoagulant activities of Idraparinux.Investigational
IfenprodilThe risk or severity of adverse effects can be increased when Ifenprodil is combined with Trolamine salicylate.Approved, Investigational, Withdrawn
IfetrobanThe risk or severity of adverse effects can be increased when Ifetroban is combined with Trolamine salicylate.Investigational
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Trolamine salicylate.Approved, Investigational
ImidaprilTrolamine salicylate may decrease the antihypertensive activities of Imidapril.Investigational
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Trolamine salicylate.Investigational
IstaroximeThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Istaroxime.Investigational
KetanserinThe risk or severity of adverse effects can be increased when Ketanserin is combined with Trolamine salicylate.Investigational
LepirudinTrolamine salicylate may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanTrolamine salicylate may increase the anticoagulant activities of Letaxaban.Investigational
LinsidomineThe risk or severity of adverse effects can be increased when Linsidomine is combined with Trolamine salicylate.Experimental
LisinoprilTrolamine salicylate may decrease the antihypertensive activities of Lisinopril.Approved, Investigational
LoteprednolThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Loteprednol.Approved
ME-609The risk or severity of adverse effects can be increased when Trolamine salicylate is combined with ME-609.Investigational
MedrysoneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Medrysone.Approved
MelagatranTrolamine salicylate may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Melengestrol.Vet Approved
MesalazineMesalazine may increase the anticoagulant activities of Trolamine salicylate.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Methazolamide.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Trolamine salicylate.Approved
Methyl salicylateMethyl salicylate may increase the anticoagulant activities of Trolamine salicylate.Approved, Vet Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Methylprednisolone.Approved, Vet Approved
MilrinoneThe risk or severity of adverse effects can be increased when Milrinone is combined with Trolamine salicylate.Approved
MoexiprilTrolamine salicylate may decrease the antihypertensive activities of Moexipril.Approved
MometasoneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Mometasone.Approved, Vet Approved
NadroparinTrolamine salicylate may increase the anticoagulant activities of Nadroparin.Approved
NafamostatTrolamine salicylate may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftopidilThe risk or severity of adverse effects can be increased when Naftopidil is combined with Trolamine salicylate.Investigational
NCX 1022The risk or severity of adverse effects can be increased when Trolamine salicylate is combined with NCX 1022.Investigational
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Trolamine salicylate.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Trolamine salicylate.Investigational
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Oleoyl-estrone.Investigational
OlsalazineOlsalazine may increase the anticoagulant activities of Trolamine salicylate.Approved
OmapatrilatTrolamine salicylate may decrease the antihypertensive activities of Omapatrilat.Investigational
OtamixabanTrolamine salicylate may increase the anticoagulant activities of Otamixaban.Investigational
OzagrelThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Ozagrel.Investigational
ParamethasoneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Paramethasone.Approved
ParnaparinThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Parnaparin.Approved, Investigational
Pentaerythritol TetranitrateTrolamine salicylate may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfateTrolamine salicylate may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PentoxifyllineThe risk or severity of adverse effects can be increased when Pentoxifylline is combined with Trolamine salicylate.Approved, Investigational
PerindoprilTrolamine salicylate may decrease the antihypertensive activities of Perindopril.Approved
PhenindioneTrolamine salicylate may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonTrolamine salicylate may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PicotamideThe risk or severity of adverse effects can be increased when Picotamide is combined with Trolamine salicylate.Experimental
PiretanideTrolamine salicylate may decrease the diuretic activities of Piretanide.Experimental
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Trolamine salicylate.Approved
PrasteroneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Prasterone.Approved, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Prasterone sulfate.Investigational
PrasugrelThe risk or severity of adverse effects can be increased when Prasugrel is combined with Trolamine salicylate.Approved
PrednicarbateThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Pregnenolone.Experimental, Investigational
ProbenecidThe therapeutic efficacy of Probenecid can be decreased when used in combination with Trolamine salicylate.Approved
Protein CTrolamine salicylate may increase the anticoagulant activities of Protein C.Approved
Protein S humanTrolamine salicylate may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeTrolamine salicylate may increase the anticoagulant activities of Protocatechualdehyde.Approved
QuinaprilTrolamine salicylate may decrease the antihypertensive activities of Quinapril.Approved, Investigational
RamatrobanThe risk or severity of adverse effects can be increased when Ramatroban is combined with Trolamine salicylate.Investigational
RamiprilTrolamine salicylate may decrease the antihypertensive activities of Ramipril.Approved
RelcovaptanThe risk or severity of adverse effects can be increased when Relcovaptan is combined with Trolamine salicylate.Investigational
RescinnamineTrolamine salicylate may decrease the antihypertensive activities of Rescinnamine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Trolamine salicylate.Approved, Experimental, Investigational
ReteplaseThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Reteplase.Approved
ReviparinTrolamine salicylate may increase the anticoagulant activities of Reviparin.Approved, Investigational
RidogrelThe risk or severity of adverse effects can be increased when Ridogrel is combined with Trolamine salicylate.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Rimexolone.Approved
RivaroxabanTrolamine salicylate may increase the anticoagulant activities of Rivaroxaban.Approved
RosiglitazoneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Rosiglitazone.Approved, Investigational
Salicylic acidSalicylic acid may increase the anticoagulant activities of Trolamine salicylate.Approved, Vet Approved
SarpogrelateThe risk or severity of adverse effects can be increased when Sarpogrelate is combined with Trolamine salicylate.Investigational
SaruplaseThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Saruplase.Experimental
SelexipagThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Selexipag.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Trolamine salicylate.Approved, Vet Approved
SpiraprilTrolamine salicylate may decrease the antihypertensive activities of Spirapril.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Trolamine salicylate.Investigational
StreptokinaseThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Streptokinase.Approved, Investigational
SulodexideTrolamine salicylate may increase the anticoagulant activities of Sulodexide.Approved, Investigational
TemocaprilTrolamine salicylate may decrease the antihypertensive activities of Temocapril.Experimental, Investigational
TenecteplaseThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Tenecteplase.Approved
TesmilifeneThe risk or severity of adverse effects can be increased when Tesmilifene is combined with Trolamine salicylate.Investigational
TicagrelorThe risk or severity of adverse effects can be increased when Ticagrelor is combined with Trolamine salicylate.Approved
TiclopidineThe risk or severity of adverse effects can be increased when Ticlopidine is combined with Trolamine salicylate.Approved
TinzaparinThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Tinzaparin.Approved
TioclomarolTrolamine salicylate may increase the anticoagulant activities of Tioclomarol.Experimental
TirofibanThe risk or severity of adverse effects can be increased when Tirofiban is combined with Trolamine salicylate.Approved
TixocortolThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Tixocortol.Approved, Withdrawn
TorasemideTrolamine salicylate may decrease the diuretic activities of Torasemide.Approved
TrandolaprilTrolamine salicylate may decrease the antihypertensive activities of Trandolapril.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Trolamine salicylate.Approved, Investigational
TrapidilThe risk or severity of adverse effects can be increased when Trapidil is combined with Trolamine salicylate.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Trolamine salicylate.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Triamcinolone.Approved, Vet Approved
TriflusalThe risk or severity of adverse effects can be increased when Triflusal is combined with Trolamine salicylate.Approved, Investigational
TroxerutinTrolamine salicylate may increase the anticoagulant activities of Troxerutin.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Ulobetasol.Approved
UrokinaseThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Urokinase.Approved, Investigational, Withdrawn
Valproic AcidThe serum concentration of Valproic Acid can be increased when it is combined with Trolamine salicylate.Approved, Investigational
VerapamilVerapamil may increase the anticoagulant activities of Trolamine salicylate.Approved
VorapaxarThe risk or severity of adverse effects can be increased when Vorapaxar is combined with Trolamine salicylate.Approved
WarfarinTrolamine salicylate may increase the anticoagulant activities of Warfarin.Approved
XimelagatranTrolamine salicylate may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZofenoprilTrolamine salicylate may decrease the antihypertensive activities of Zofenopril.Experimental
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
25213
PubChem Substance
347827887
ChemSpider
23549
ChEMBL
CHEMBL2107288
AHFS Codes
  • 28:08.04.24 — Salicylates

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1RecruitingTreatmentMinor burns1
2Not Yet RecruitingTreatmentToothache1
3CompletedTreatmentNon-Hodgkin's Lymphoma (NHL)1
3CompletedTreatmentPain, Neuropathic1
4CompletedTreatmentCaudal epidural block therapy / Forearm Injuries / Orthopedic Procedures / Traumas / Upper Extremity1
4CompletedTreatmentCaudal epidural block therapy / Orthopedic Procedures / Shoulder1
Not AvailableCompletedTreatmentCerebral Palsy (CP)1
Not AvailableCompletedTreatmentLow Back Pain (LBP) / Pain1
Not AvailableCompletedTreatmentRecession, Gingival1
Not AvailableRecruitingBasic ScienceHeart Failure, Unspecified1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
CreamTopical10 g/100mL
OintmentTopical13.3 %
CreamTopical10 g/100g
LotionTopical10 %
SprayTopical100 mg/mL
SprayTopical.1 g/100mL
CreamTopical8.5 g/85g
SprayTopical10 g/100mL
LiquidTopical10 g/100g
GelTopical15 %
LotionTopical
LotionTopical10.0 %
CreamTopical
CreamTopical13.3 %
CreamTopical15 %
CreamTopical100 mg/g
PatchTopical12.5 %
GelTopical
CreamCutaneous10 g/1
CreamTopical20 %
PatchTopical
CreamTopical10 %
LotionTopical10 g/100mL
LiquidTopical100 mg/mL
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility11.3 mg/mLALOGPS
logP1.96ALOGPS
logP1.98ChemAxon
logS-1.1ALOGPS
pKa (Strongest Acidic)2.79ChemAxon
pKa (Strongest Basic)-6.3ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area57.53 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity35.3 m3·mol-1ChemAxon
Polarizability12.82 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as 1,2-aminoalcohols. These are organic compounds containing an alkyl chain with an amine group bound to the C1 atom and an alcohol group bound to the C2 atom.
Kingdom
Organic compounds
Super Class
Organic nitrogen compounds
Class
Organonitrogen compounds
Sub Class
Amines
Direct Parent
1,2-aminoalcohols
Alternative Parents
Trialkylamines / Monocarboxylic acids and derivatives / Primary alcohols / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Tertiary aliphatic amine / Tertiary amine / 1,2-aminoalcohol / Monocarboxylic acid or derivatives / Organic oxygen compound / Organopnictogen compound / Hydrocarbon derivative / Primary alcohol / Organooxygen compound / Alcohol
Molecular Framework
Not Available
External Descriptors
Not Available

Drug created on December 03, 2015 09:51 / Updated on January 22, 2018 10:46